
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics is a healthcare service provider with a promising clinical program pipeline, which includes three products with significant potential for treating metabolic and endocrine disorders. The company has a strong partnership in place with Ligand Pharmaceuticals and has taken meaningful steps to advance its VK2809 program. Despite facing standard industry risks, Viking Therapeutics shows potential for successful clinical outcomes and an attractive valuation for investors.
Bears say
Viking Therapeutics is a healthcare service provider focusing on metabolic and endocrine disorders, with a pipeline primarily composed of VK2809, VK5211, and VK0214 products. Despite positive data for VK2809 and VK0214, the absence of a plateau in the clinical trial for VK5211 could indicate potential upside for the company's phase III VANQUISH doses. The transition to an auto-injector for VK2735 shows confidence in its potential, but there is still a risk that VK2735 may not replicate the weight loss and tolerability in Phase 3 trials as seen in Phase 2 trials.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares